Cytokine gene polymorphisms are associated with irritable bowel syndrome: A systematic review and meta-analysis

Neurogastroenterology and Motility

Volumn 24, Issue 12, 2012, Pages

  Bashashati, M ^a   Rezaei, N ^b,c   Bashashati, H ^d   Shafieyoun, A ^b   Daryani, N E ^b   Sharkey, K A ^a   Storr, M ^a,e  

^a UNIVERSITY OF CALGARY   (Canada)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cytokine; Genetic polymorphism; Irritable bowel syndrome

Indexed keywords

INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR;

ARTICLE; DNA POLYMORPHISM; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; IRRITABLE COLON; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

CYTOKINES; HUMANS; INTERLEUKIN-10; IRRITABLE BOWEL SYNDROME; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870298788     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2012.01990.x     Document Type: Article

References (52)

1. Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med 2008; 358: 1692-9.
2. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-73.
3. Schwille-Kiuntke J, Frick JS, Zanger P, Enck P. Post-infectious irritable bowel syndrome - a review of the literature. Z Gastroenterol 2011; 49: 997-1003.
4. Connor BA. Sequelae of traveler's diarrhea: focus on postinfectious irritable bowel syndrome. Clin Infect Dis 2005; 41(Suppl. 8): S577-86.
5. Bashashati M, Rezaei N, Andrews CN et al. Cytokines and irritable bowel syndrome: where do we stand? Cytokine 2012; 57: 201-9.
6. Elsenbruch S, Holtmann G, Oezcan D et al. Are there alterations of neuroendocrine and cellular immune responses to nutrients in women with irritable bowel syndrome? Am J Gastroenterol 2004; 99: 703-10.
7. Dinan TG, Quigley EM, Ahmed SM et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 304-11.
8. Ohman L, Isaksson S, Lindmark AC et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104: 1205-12.
9. Khan WI, Blennerhassett PA, Deng Y, Gauldie J, Vallance BA, Collins SM. IL-12 gene transfer alters gut physiology and host immunity in nematode-infected mice. Am J Physiol Gastrointest Liver Physiol 2001; 281: G102-10.
10. Akiho H, Deng Y, Blennerhassett P, Kanbayashi H, Collins SM. Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction. Gastroenterology 2005; 129: 131-41.
11. Al-Sadi R, Boivin M, Ma T. Mechanism of cytokine modulation of epithelial tight junction barrier. Front Biosci 2009; 14: 2765-78.
12. O'Mahony SM, Marchesi JR, Scully P et al. Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol Psychiatry 2009; 65: 263-7.
13. Roberts-Thomson IC, Fon J, Uylaki W, Cummins AG, Barry S. Cells, cytokines and inflammatory bowel disease: a clinical perspective. Expert Rev Gastroenterol Hepatol 2011; 5: 703-16.
14. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor-alpha genes: a technical report. Transpl Immunol 1998; 6: 193-7.
15. Barkhordari E, Rezaei N, Ansaripour B et al. Proinflammatory cytokine gene polymorphisms in irritable bowel syndrome. J Clin Immunol 2010; 30: 74-9.
16. Barkhordari E, Rezaei N, Mahmoudi M et al. T-helper 1, T-helper 2, and T-regulatory cytokines gene polymorphisms in irritable bowel syndrome. Inflammation 2010; 33: 281-6.
17. Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003; 52: 91-3.
18. van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005; 100: 2510-6.
19. Santhosh S, Dutta AK, Samuel P, Joseph AJ, Ashok KJ, Kurian G. Cytokine gene polymorphisms in irritable bowel syndrome in Indian population - a pilot case control study. Trop Gastroenterol 2010; 31: 30-3.
20. Lee HJ, Lee SY, Choi JE et al. G protein beta3 subunit, interleukin-10, and tumor necrosis factor-alpha gene polymorphisms in Koreans with irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 758-63.
21. Xie C, Liu XF, Yang MS. A meta-analysis on the association between three promoter variants of TNF-alpha and Crohn's disease. Mol Biol Rep 2012; 39: 1575-83.
22. Barkhordari E, Amirzargar AA, Ebrahimi-Daryani N et al. Lack of association between interleukin 12 C(-1188)A polymorphism and irritable bowel syndrome. Avicenna J Med Biotech 2011; 3: 45-8.
23. Stewart MJ, Seow CH, Storr MA. Prednisolone and budesonide for short- and long-term treatment of microscopic colitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2011; 9: 881-90.
24. Gwee KA. Post-infectious irritable bowel syndrome, an inflammation-immunological model with relevance for other IBS and functional dyspepsia. J Neurogastroenterol Motil 2010; 16: 30-4.
25. O'Mahony L, McCarthy J, Kelly P et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-51.
26. Kindt S, Van OL, Broekaert D et al. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2009; 21: 389-98.
27. Scully P, McKernan DP, Keohane J et al. Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010; 105: 2235-43.
28. Hua MC, Lai MW, Kuo ML, Yao TC, Huang JL, Chen SM. Decreased interleukin-10 secretion by peripheral blood mononuclear cells in children with irritable bowel syndrome. J Pediatr Gastroenterol Nutr 2011; 52: 376-81.
29. Chang L, Adeyemo M, Karagiannidis I et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2011; 107: 262-72.
30. Del Valle-Pinero AY, Martino AC, Taylor TJ et al. Pro-inflammatory chemokine C-C motif ligand 16 (CCL-16) dysregulation in irritable bowel syndrome (IBS): a pilot study. Neurogastroenterol Motil 2011; 23: 1092-7.
31. Schmulson M, Pulido-London D, Rodriguez O et al. Lower serum IL-10 is an independent predictor of IBS among volunteers in Mexico. Am J Gastroenterol 2012; 107: 747-53.
32. Macsharry J, O'Mahony L, Fanning A et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 2008; 43: 1467-76.
33. Kucharzik T, Stoll R, Lugering N, Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 100: 452-6.
34. Mitsuyama K, Tomiyasu N, Takaki K et al. Interleukin-10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase. Mediators Inflamm 2006; 2006: 26875.
35. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun 2000; 1: 185-90.
36. Nielsen OH, Koppen T, Rudiger N, Horn T, Eriksen J, Kirman I. Involvement of interleukin-4 and -10 in inflammatory bowel disease. Dig Dis Sci 1996; 41: 1786-93.
37. Sabat R, Grutz G, Warszawska K et al. Biology of interleukin-10. Cytokine Growth Factor Rev 2010; 21: 331-44.
38. Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 1434-44.
39. Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-20.
40. Lu Z, Chen L, Li H, Zhao Y, Lin L. Effect of the polymorphism of tumor necrosis factor-alpha-308 G/A gene promoter on the susceptibility to ulcerative colitis: a meta-analysis. Digestion 2008; 78: 44-51.
41. Ng SC, Tsoi KK, Kamm MA et al. Genetics of inflammatory bowel disease in Asia: systematic review and meta-analysis. Inflamm Bowel Dis 2011; 18: 1164-76.
42. Han Z, Li C, Han S et al. Meta-analysis: polymorphisms in TNF-alpha gene promoter and Crohn's disease. Aliment Pharmacol Ther 2010; 32: 159-70.
43. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia - a systematic review. J Gastroenterol Hepatol 2012; 27: 1266-80.
44. Ghoshal UC, Ranjan P. Post-infectious irritable bowel syndrome: the past, the present and the future. J Gastroenterol Hepatol 2011; 26(Suppl. 3): 94-101.
45. Villani AC, Lemire M, Thabane M et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010; 138: 1502-13.
46. Kulkarni AB, Karlsson S. Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol 1993; 143: 3-9.
47. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66: 1014-20.
48. Suthanthiran M. Clinical application of molecular biology: a study of allograft rejection with polymerase chain reaction. Am J Med Sci 1997; 313: 264-7.
49. Wouters MM. New insight in the pathogenesis of functional gastrointestinal disorders: association between genetics and colonic transit. Neurogastroenterol Motil 2011; 23: 893-7.
50. Dinan TG, Cryan J, Shanahan F, Keeling PW, Quigley EM. IBS: an epigenetic perspective. Nat Rev Gastroenterol Hepatol 2010; 7: 465-71.
51. Corinaldesi R, Stanghellini V, Cremon C et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009; 30: 245-52.
52. Andrews CN, Griffiths TA, Kaufman J, Vergnolle N, Surette MG, Rioux KP. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011; 34: 374-83.